Drug intelligence / Profile preview

macupatide

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Macupatide (LY3532226) is a recombinant polypeptide being developed by Eli Lilly as a gastric inhibitory polypeptide receptor (GIPR) agonist. It is currently in clinical trials for the treatment of obesity, type 1 diabetes mellitus, and hypoglycemia. The drug is administered subcutaneously and is being evaluated for both weekly and monthly dosing regimens. Clinical trials are assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in various patient populations.

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on macupatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on macupatide.

Explore the full profile